IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors

Cancer Letters

Volumn 338, Issue 2, 2013, Pages 239-248

  Porter, Holly A ^a   Perry, Anthony ^b   Kingsley, Chris ^c   Tran, Nhan L ^c   Keegan, Achsah D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer; Cell death; Chemotherapy; Insulin receptor substrate; STAT6

Indexed keywords

DOXORUBICIN; ESTROGEN RECEPTOR ALPHA; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LENTIVIRUS VECTOR; LIPOCORTIN 2; PACLITAXEL; SHORT HAIRPIN RNA; STAT6 PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GRADING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; TUMOR INVASION;

BREAST CANCER; CELL DEATH; CHEMOTHERAPY; INSULIN RECEPTOR SUBSTRATE; STAT6;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MCF-7 CELLS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PACLITAXEL; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 84881667652     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.03.030     Document Type: Article

References (56)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int. J. Cancer 2008, 127(2010):2893-2917.
2. Munagala R., Aqil F., Gupta R.C. Promising molecular targeted therapies in breast cancer. Indian J. Pharmacol. 2011, 43:236-245.
3. Breast cancer, A.D.A.M, 1993. <> (Accessed 23.02.12). http://www.nlm.nih.gov/medlineplus/ency/article/000913.htm#Definition.
4. Wang M.Y., Chen P.S., Prakash E., Hsu H.C., Huang H.Y., Lin M.T., et al. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res. 2009, 69:3482-3491.
5. Romagnani S. The Th1/Th2 paradigm. Immunol. Today 1997, 18:263-266.
6. Conticello C., Pedini F., Zeuner A., Patti M., Zerilli M., Stassi G., et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J. Immunol. 2004, 172:5467-5477.
7. Todaro M., Lombardo Y., Francipane M.G., Alea M.P., Cammareri P., Iovino F., et al. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ. 2008, 15:762-772.
8. Li Z., Chen L., Qin Z. Paradoxical roles of IL-4 in tumor immunity. Cell. Mol. Immunol. 2009, 6:415-422.
9. Zhang W.J., Li B.H., Yang X.Z., Li P.D., Yuan Q., Liu X.H., et al. IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells. Cytokine 2008, 42:39-47.
10. White M.F. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol. Cell. Biochem. 1998, 182:3-11.
11. Bruning J.C., Winnay J., Cheatham B., Kahn C.R. Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells. Mol. Cell. Biol. 1997, 17:1513-1521.
12. Withers D.J., White M. Perspective: the insulin signaling system-a common link in the pathogenesis of type 2 diabetes. Endocrinology 2000, 141:1917-1921.
13. Keegan A.D., Zamorano J. Regulation of gene expression, growth, and cell survival by IL-4: contribution of multiple signaling pathways. Cell Res. 1998, 8:1-13.
14. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
15. Byron S.A., Horwitz K.B., Richer J.K., Lange C.A., Zhang X., Yee D. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br. J. Cancer 2006, 95:1220-1228.
16. Ma Z., Gibson S.L., Byrne M.A., Zhang J., White M.F., Shaw L.M. Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis. Mol. Cell. Biol. 2006, 26:9338-9351.
17. Shaw L.M. Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol. Cell. Biol. 2001, 21:5082-5093.
18. Nagle J.A., Ma Z., Byrne M.A., White M.F., Shaw L.M. Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol. Cell. Biol. 2004, 24:9726-9735.
19. Mardilovich K., Pankratz S.L., Shaw L.M. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun. Signal. 2009, 7:14.
20. Gibson S.L., Ma Z., Shaw L.M. Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle 2007, 6:631-637.
21. Jackson J.G., Zhang X., Yoneda T., Yee D. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene 2001, 20:7318-7325.
22. Cui X., Kim H.J., Kuiatse I., Kim H., Brown P.H., Lee A.V. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res. 2006, 66:5304-5313.
23. Zhang X., Kamaraju S., Hakuno F., Kabuta T., Takahashi S., Sachdev D., et al. Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res. Treat. 2004, 83:161-170.
24. Porter H.A., Carey G.B., Keegan A.D. Insulin receptor substrate 1 expression enhances the sensitivity of 32D cells to chemotherapy-induced cell death. Exp. Cell Res. 2012.
25. Willis A.L., Tran N.L., Chatigny J.M., Charlton N., Vu H., Brown S.A., et al. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol. Cancer Res. 2008, 6:725-734.
26. Teo H., Ghosh S., Luesch H., Ghosh A., Wong E.T., Malik N., et al. Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression. Nat. Cell Biol. 2010, 12:758-767.
27. Whitsett T.G., Cheng E., Inge L., Asrani K., Jameson N.M., Hostetter G., et al. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am. J. Pathol. 2012.
28. Fortin S.P., Ennis M.J., Savitch B.A., Carpentieri D., McDonough W.S., Winkles J.A., et al. Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. Mol. Cancer Res. 2009, 7:1871-1881.
29. Schnarr B., Strunz K., Ohsam J., Benner A., Wacker J., Mayer D. Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int. J. Cancer 2000, 89:506-513.
30. Clark J.L., Dresser K., Hsieh C.C., Sabel M., Kleer C.G., Khan A., et al. Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancer. Breast Cancer Res. Treat. 2011.
31. Sisci D., Morelli C., Garofalo C., Romeo F., Morabito L., Casaburi F., et al. Expression of nuclear insulin receptor substrate 1 in breast cancer. J. Clin. Pathol. 2007, 60:633-641.
32. Molloy C.A., May F.E., Westley B.R. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J. Biol. Chem. 2000, 275:12565-12571.
33. Obiri N.I., Siegel J.P., Varricchio F., Puri R.K. Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin. Exp. Immunol. 1994, 95:148-155.
34. Burt B.M., Bader A., Winter D., Rodig S.J., Bueno R., Sugarbaker D.J. Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. Clin. Cancer Res. 2012, 18:1568-1577.
35. Jackson J.G., White M.F., Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J. Biol. Chem. 1998, 273:9994-10003.
36. De S., Cipriano R., Jackson M.W., Stark G.R. Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res. 2009, 69:8035-8042.
37. Wang T.H., Popp D.M., Wang H.S., Saitoh M., Mural J.G., Henley D.C., et al. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J. Biol. Chem. 1999, 274:8208-8216.
38. Zhou J., Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr. Med. Chem. Anticancer Agents 2005, 5:65-71.
39. Momparler R.L., Karon M., Siegel S.E., Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 1976, 36:2891-2895.
40. Koehn H., Magan N., Isaacs R.J., Stowell K.M. Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin. Anticancer Drugs 2007, 18:419-425.
41. Beere H.M., Chresta C.M., Alejo-Herberg A., Skladanowski A., Dive C., Larsen A.K., et al. Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis. Mol. Pharmacol. 1995, 47:986-996.
42. Zhao H., Rybak P., Dobrucki J., Traganos F., Darzynkiewicz Z. Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide. Cytometry A 2012, 81:45-51.
43. Aubel-Sadron G., Londos-Gagliardi D. Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie 1984, 66:333-352.
44. Chumsri S., Howes T., Bao T., Sabnis G., Brodie A. Aromatase, aromatase inhibitors, and breast cancer. J. Steroid Biochem. Mol. Biol. 2011, 125:13-22.
45. Glick J.H., Creech R.H., Torri S., Holroyde C., Brodovsky H., Catalano R.B., et al. Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial. Cancer 1980, 45:735-741.
46. Dearth R.K., Cui X., Kim H.J., Hadsell D.L., Lee A.V. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 2007, 6:705-713.
47. Cui X., Lazard Z., Zhang P., Hopp T.A., Lee A.V. Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2. Oncogene 2003, 22:6937-6941.
48. Vassen L., Wegrzyn W., Klein-Hitpass L. Human insulin receptor substrate-2 (IRS-2) is a primary progesterone response gene. Mol. Endocrinol. 1999, 13:485-494.
49. Rocha R.L., Hilsenbeck S.G., Jackson J.G., VanDenBerg C.L., Weng C., Lee A.V., et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin. Cancer Res. 1997, 3:103-109.
50. Koda M., Sulkowska M., Kanczuga-Koda L., Sulkowski S. Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases. J. Clin. Pathol. 2005, 58:645-649.
51. Gual P., Le Marchand-Brustel Y., Tanti J.F. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 2005, 87:99-109.
52. Lippman M.E., Allegra J.C., Thompson E.B., Simon R., Barlock A., Green L., et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N. Engl. J. Med. 1978, 298:1223-1228.
53. Kiang D.T., Frenning D.H., Goldman A.I., Ascensao V.F., Kennedy B.J. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N. Engl. J. Med. 1978, 299:1330-1334.
54. Surmacz E., Burgaud J.L. Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clin. Cancer Res. 1995, 1:1429-1436.
55. Guvakova M.A., Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res. 1997, 57:2606-2610.
56. Salerno M., Sisci D., Mauro L., Guvakova M.A., Ando S., Surmacz E. Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int. J. Cancer 1999, 81:299-304.